真实生物三度递表港交所 核心产品阿兹夫定在中国获附条件批准用于治疗HIV感染及COVID-19

Company Overview - Real Bio Technology Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange, with China International Capital Corporation as its sole sponsor. This marks the company's third attempt to list, following previous submissions in August 2022 and February 2025 [1] - Established in 2012, Real Bio focuses on the innovative research and development of drugs for viral infections, tumors, and cardiovascular diseases. The company has developed a comprehensive drug pipeline, including five candidate drugs [4][5] Product Pipeline - The core product, Azvudine, has received conditional approval in China for the treatment of HIV and COVID-19. The company is developing monotherapy and combination therapies for various cancers and HIV [4][5] - Other key products include CL-197 for long-term HIV treatment, Doshitini for non-small cell lung cancer, ZSSW-136 for malignant tumors, and MTB-1806 for acute ischemic stroke [4][5] Production and Commercialization - Real Bio has established its own production facilities with an annual capacity of approximately 3 billion tablets, certified by GMP, to meet commercialization needs. The company has a professional commercialization team and a comprehensive management system [6] - Azvudine was included in the National Reimbursement Drug List (NRDL) in 2023 and successfully renewed its status in 2024, ensuring price stability and broad market access [6] Financial Performance - For the fiscal year ending December 31, 2023, the company reported revenues of 344.21 million RMB, with a gross loss of 329.41 million RMB. The majority of revenue was derived from Azvudine, with significant R&D expenses impacting profitability [8][9][11] - The company recorded a net loss of 783.58 million RMB for 2023, primarily due to high R&D costs and administrative expenses [11] Market Overview - The global antiviral drug market was valued at $73.6 billion in 2023, with a projected compound annual growth rate (CAGR) of 6.3% from 2023 to 2030. The Chinese antiviral drug market is expected to grow from $7.8 billion in 2023 to $21.8 billion by 2030, with a CAGR of 15.8% [12][14] - The global HIV drug market reached $43.1 billion in 2023, with a projected CAGR of 4.1% through 2030. In China, the HIV drug market is expected to grow from $636.2 million in 2023 to $2.33 billion by 2030, with a CAGR of 20.4% [16][17] Board and Shareholding Structure - The board of directors consists of eight members, including three executive directors and three independent non-executive directors, responsible for overall management and strategic direction [25] - The founder, Wang Chaoyang, holds a combined 48.12% stake in the company through various investment vehicles [28][30]